World
CONTACTAbout UsCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2025 Equal Entertainment LLC.
All Rights reserved
All Rights reserved
By continuing to use our site, you agree to our Private Policy and Terms of Use.
Boehringer Ingelheim launches expanded access for Tipranavir
Drugmaker Boehringer Ingelheim on Tuesday announced the launch of an expanded access program for its experimental protease inhibitor Tipranavir. The program provides access to the drug for all treatment-experienced HIV patients not enrolled in the ongoing clinical study of Tipranavir who have demonstrated resistance to other protease inhibitors. Eligibility for the program is not limited by CD4-cell counts or HIV viral loads. Tipranavir is currently in Phase III studies and was submitted to the Food and Drug Administration for marketing approval in late October. A decision by the FDA is expected by April. Tipranavir is a nonpeptidic drug, unlike other protease inhibitors, giving it a unique resistance profile and making it effective for most HIV patients resistant to other protease drugs. For more information about the expanded access program, health care providers can call (888) 524-8675 or go online to www.tpv-eap.com.
From our Sponsors
Most Popular
31 Period Films of Lesbians and Bi Women in Love That Will Take You Back
December 09 2024 1:00 PM
18 of the most batsh*t things N.C. Republican governor candidate Mark Robinson has said
October 30 2024 11:06 AM
True
These 15 major companies caved to the far right and stopped DEI programs
January 24 2025 1:11 PM
True
Latest Stories
Senate staffer accused of having sex in Capitol building recounts 'horrific' backlash
April 21 2025 12:03 PM
Pope Francis dead at 88: Looking back on his LGBTQ+ rights legacy
April 21 2025 5:37 AM
Federal appeals court upholds block on Trump's trans military ban
April 19 2025 11:17 AM
From Roe to woes, the days SCOTUS hit 'undo' on half a century of progress
April 19 2025 7:00 AM
Federal judge blocks Trump admin's gender-restrictive passport policy
April 18 2025 8:13 PM